Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470275 · ClinicalTrials.gov registry record · Phase 2
Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
A Phase 2 study of Sarcoma, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 20
- Study locations
NCT00470275: Completed Phase 2 study of Sarcoma, sponsored by Children's Oncology Group.
NCT00470275 is a Phase 2 study of Sarcoma that has completed, run by Children's Oncology Group. The registered enrollment target is 10 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00470275, a Phase 2 study of Sarcoma, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well cytarabine works in treating young patients with recurrent or refractory Ewing's sarcoma.
Primary Outcome
Any patient who is enrolled and receives at least one dose of cytarabine will be considered evaluable for response if (1) the patient demonstrates progressive disease while on protocol therapy or (2) the patient is observed on protocol therapy for at least one cycle. Patients who achieve a complete or partial response according to the RECIST (Response Evaluation Criteria In Solid Tumors) criteria will be considered responders for the study design. All other patients who are evaluable for respons
Conditions Studied
Interventions
- DRUG cytarabine
Study Locations (20)
California
- Southern California Permanente Medical Group - Downey
- Children's Hospital Central California - Madera
- Children's Hospital of Orange County - Orange
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Florida
- Lee Cancer Care of Lee Memorial Health System - Fort Myers
- All Children's Hospital - St. Petersburg
- St. Joseph's Cancer Institute at St. Joseph's Hospital - Tampa
- Kaplan Cancer Center at St. Mary's Medical Center - West Palm Beach
Illinois
- Children's Memorial Hospital - Chicago - Chicago
- Simmons Cooper Cancer Institute - Springfield
Alabama
- Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham - Birmingham
Arizona
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center - Farmington
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
What the finished NCT00470275 record still lists
NCT00470275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which cytarabine is the first listed.
NCT00470275 names 20 study sites across 13 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00470275 about?
NCT00470275 is a clinical study titled "Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma". RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well cytarabine works in treating young patients with recurrent or refract...
What is the current status of trial NCT00470275?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2007-05. Estimated completion is 2013-12.
What conditions does trial NCT00470275 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT00470275?
The interventions under investigation include: cytarabine (DRUG).
Who is sponsoring clinical trial NCT00470275?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00470275 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00470275's enrollment target sits among peer trials
10 116th of 122 higher than 6 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia